Drug shortage
Dextrose Monohydrate 5% Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · To Be Discontinued · updated Dec 3, 2025
Key facts
| Generic name | Dextrose Monohydrate 5% Injection |
|---|---|
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Dextrose 5% In Plastic Container, Injection, 5 g/100mL (5%) Plastic (NDC 0409-7100-67) |
| Dosage form | Injection |
| Status | To Be Discontinued |
| Therapeutic category | Endocrinology/Metabolism Gastroenterology Other Pediatric |
| Package NDCs | 0409-7100-67 |
| First posted | Feb 14, 2022 |
| Last updated | Dec 3, 2025 |
| Discontinued | Dec 3, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: